Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 57.1%

Neg 57.1% Neu 0% Pos 0%

Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and lowers the price target from $3 to $1.